Current issue
Archive
Online first
About the Journal
Editorial Board
Scientific Board
Reviewers
Abstracting and indexing
Publisher
Contact
Subscription
Ethical standards and procedures
Abstracting and indexing
For authors
Ethical standards and procedures
Publication charge
Books and Events
Books
Events
CASE REPORT
Switching to faricimab in cases of limited response to aflibercept in patients with neovascular age-related macular degeneration – report of two clinical cases
1
Department of Vitreoretinal Surgery, Medical University of Lublin
Publication date: 2026-05-25
Ophthalmology 2026;29(1):17-20
KEYWORDS
neovascular form age-related macular degeneration (nAMD)anti-vascular endothelial growth factor (anti-VEGF) agentsfaricimabaflibercept
ABSTRACT
Age-related macular degeneration is the leading cause of vision loss among elderly patients. Treatment for the exudative (neovascular) form of age-related macular degeneration involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. However, this therapy is long term and burdensome, and therefore new substances and treatment regimens are being sought. According to scientific reports and real-world clinical observations, switching to a different drug during treatment is beneficial for many patients. This paper presents two clinical cases in which switching medications during anti-vascular endothelial growth factor therapy proved beneficial both functionally and morphologically.
REFERENCES (10)
1.
Fleckenstein M, Keenan TDL, Guymer RH, et al.: Age-related macular degeneration. Nat Rev Dis Primers. 2021; 7(1): 31. Published 2021 May 6. doi:10.1038/s41572-021-00265-2.
2.
Solomon SD, Lindsley K, Vedula SS, et al.: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 2019; Issue 3. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub4. Accessed 21 April 2026.
3.
Amoaku W, Chakravarthy U, Gale R, et al.: Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015; 29: 721–731. https://doi.org/10.1038/eye.20....
4.
World Health Organization. World report on vision; 2019. Available from: https://www.who.int/publicatio.... Accessed February 20, 2022.
5.
Deng Y, Qiao L, Du M, et al.: Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2021; 9(1): 62–79. Published 2021 Feb 27. doi:10.1016/j.gendis.2021.02.009.
6.
Melincovici CS, Boşca AB, Şuşman S, et al.: Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018; 59(2): 455–467.
7.
Rosenberg D, Deonarain DM, Gould J, et al.: Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023; 37(1): 6–16. doi:10.1038/s41433-022-02020-7.
8.
Mitchell P, Holz FG, Hykin P, et al.: Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES Study: A Randomized Clinical Trial. Retina. 2021; 41(9): 1911–1920. doi:10.1097/IAE.0000000000003128.
9.
Heier JS, Khanani AM, Quezada Ruiz C, et al.: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326): 729–740. doi:10.1016/S0140-6736(22)00010-1.
10.
Wong DT, Aboobaker S, Maberley D, et al.: Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025; 10(1): e001967. Published 2025 Jan 16. doi:10.1136/bmjophth-2024-001967.
| eISSN: | 1689-362X |
| ISSN: | 1505-2753 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
